DK1276738T3 - 2-amino-3- (alkyl) - pyrimidinderivater som GSK3-betainhibitorer - Google Patents
2-amino-3- (alkyl) - pyrimidinderivater som GSK3-betainhibitorerInfo
- Publication number
- DK1276738T3 DK1276738T3 DK01959921T DK01959921T DK1276738T3 DK 1276738 T3 DK1276738 T3 DK 1276738T3 DK 01959921 T DK01959921 T DK 01959921T DK 01959921 T DK01959921 T DK 01959921T DK 1276738 T3 DK1276738 T3 DK 1276738T3
- Authority
- DK
- Denmark
- Prior art keywords
- gsk3
- betaine
- inhibitors
- amino
- alkyl
- Prior art date
Links
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 title 1
- 102000001267 GSK3 Human genes 0.000 title 1
- 108060006662 GSK3 Proteins 0.000 title 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 title 1
- 229960003237 betaine Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00400800A EP1136482A1 (en) | 2000-03-23 | 2000-03-23 | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| PCT/EP2001/003640 WO2001070729A1 (en) | 2000-03-23 | 2001-03-22 | 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1276738T3 true DK1276738T3 (da) | 2008-04-21 |
Family
ID=8173604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01959921T DK1276738T3 (da) | 2000-03-23 | 2001-03-22 | 2-amino-3- (alkyl) - pyrimidinderivater som GSK3-betainhibitorer |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6844335B2 (enExample) |
| EP (2) | EP1136482A1 (enExample) |
| JP (1) | JP4778657B2 (enExample) |
| KR (1) | KR100820543B1 (enExample) |
| CN (2) | CN1247567C (enExample) |
| AR (1) | AR028280A1 (enExample) |
| AT (1) | ATE380806T1 (enExample) |
| AU (1) | AU2001281487A1 (enExample) |
| CA (1) | CA2401241C (enExample) |
| CY (1) | CY1107236T1 (enExample) |
| DE (1) | DE60131844T2 (enExample) |
| DK (1) | DK1276738T3 (enExample) |
| ES (1) | ES2296783T3 (enExample) |
| PT (1) | PT1276738E (enExample) |
| SI (1) | SI1276738T1 (enExample) |
| WO (1) | WO2001070729A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| SE518184C2 (sv) | 2000-03-31 | 2002-09-03 | Perstorp Flooring Ab | Golvbeläggningsmaterial innefattande skivformiga golvelement vilka sammanfogas med hjälp av sammankopplingsorgan |
| IL152023A0 (en) | 2000-04-26 | 2003-04-10 | Eisai Co Ltd | Compounds having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same |
| BR0212892A (pt) * | 2001-09-21 | 2004-08-03 | Mitsubishi Pharma Corp | Derivados de 4-pirimidona-3-substituìdo |
| ES2256540T3 (es) | 2001-09-21 | 2006-07-16 | Mitsubishi Pharma Corporation | Derivados de 3-sustituido-4-pirimidona. |
| TWI335221B (en) * | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| TWI301834B (en) * | 2001-10-22 | 2008-10-11 | Eisai R&D Man Co Ltd | Pyrimidone compound and pharmaceutical composition including the same |
| TWI330183B (enExample) | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| MXPA05006394A (es) | 2002-12-16 | 2007-04-16 | Mitsubishi Pharma Corp | Derivados de 4-pirimidona 3-sustituida. |
| EP1460076A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
| EP1460075A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives |
| JP4887139B2 (ja) | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| BRPI0413452A (pt) | 2003-08-13 | 2006-10-17 | Takeda Pharmaceutical | composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv |
| EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005076854A2 (en) * | 2004-02-04 | 2005-08-25 | Smithkline Beecham Corporation | Pyrimidinone compounds useful as kinase inhibitors |
| AU2004318013B8 (en) | 2004-03-15 | 2011-10-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1768679B1 (en) * | 2004-07-09 | 2012-08-22 | Agency for Science, Technology and Research | Modulation of gsk-3beta and method of treating proliferative disorders |
| TW200621760A (en) | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
| MX2007003722A (es) | 2004-09-29 | 2007-05-23 | Mitsubishi Pharma Corp | Derivados de 6-(piridinil)-4-pirimidona como inhibidores de la tau proteina cinasa 1. |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| EP1885454A2 (en) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| ZA200802857B (en) | 2005-09-14 | 2009-09-30 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| ATE530540T1 (de) * | 2006-08-23 | 2011-11-15 | Pfizer Prod Inc | Pyrimidonverbindungen als gsk-3-inhibitoren |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| AR076014A1 (es) * | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
| US9006232B2 (en) | 2009-08-13 | 2015-04-14 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives |
| US8940738B2 (en) | 2009-08-13 | 2015-01-27 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone compounds |
| US20170209488A1 (en) | 2014-07-17 | 2017-07-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for treating neuromuscular junction-related diseases |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| WO2025215108A1 (en) * | 2024-04-10 | 2025-10-16 | Universitat De Barcelona | DUAL G9A/GSK-3ß INHIBITORS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4935631B1 (enExample) | 1970-12-28 | 1974-09-25 | ||
| JPS4935633B1 (enExample) | 1970-12-30 | 1974-09-25 | ||
| JPS559099B2 (enExample) * | 1972-08-07 | 1980-03-07 | ||
| JPS4935633A (enExample) | 1972-08-09 | 1974-04-02 | ||
| US4460589A (en) * | 1980-10-03 | 1984-07-17 | The Upjohn Company | Process for treating hypertension |
| TW229142B (enExample) * | 1992-04-15 | 1994-09-01 | Nissan Detrochem Corp | |
| US6153618A (en) * | 1996-10-11 | 2000-11-28 | Chiron Corporation | Inhibitors of glycogen synthase 3 kinase |
| CA2274093C (en) * | 1996-12-05 | 2006-11-07 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds and their use |
| WO1998024782A2 (en) * | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
| AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
-
2000
- 2000-03-23 EP EP00400800A patent/EP1136482A1/en not_active Withdrawn
-
2001
- 2001-03-22 DE DE60131844T patent/DE60131844T2/de not_active Expired - Lifetime
- 2001-03-22 WO PCT/EP2001/003640 patent/WO2001070729A1/en not_active Ceased
- 2001-03-22 KR KR1020027012431A patent/KR100820543B1/ko not_active Expired - Fee Related
- 2001-03-22 JP JP2001568932A patent/JP4778657B2/ja not_active Expired - Fee Related
- 2001-03-22 DK DK01959921T patent/DK1276738T3/da active
- 2001-03-22 AU AU2001281487A patent/AU2001281487A1/en not_active Abandoned
- 2001-03-22 US US10/221,598 patent/US6844335B2/en not_active Expired - Fee Related
- 2001-03-22 AT AT01959921T patent/ATE380806T1/de active
- 2001-03-22 ES ES01959921T patent/ES2296783T3/es not_active Expired - Lifetime
- 2001-03-22 CN CNB018069916A patent/CN1247567C/zh not_active Expired - Fee Related
- 2001-03-22 SI SI200130806T patent/SI1276738T1/sl unknown
- 2001-03-22 EP EP01959921A patent/EP1276738B8/en not_active Expired - Lifetime
- 2001-03-22 PT PT01959921T patent/PT1276738E/pt unknown
- 2001-03-22 CA CA2401241A patent/CA2401241C/en not_active Expired - Fee Related
- 2001-03-22 CN CNA2006100061354A patent/CN1891220A/zh active Pending
- 2001-03-23 AR ARP010101372A patent/AR028280A1/es active IP Right Grant
-
2005
- 2005-01-13 US US11/035,264 patent/US7378413B2/en not_active Expired - Fee Related
-
2008
- 2008-03-07 CY CY20081100270T patent/CY1107236T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1419552A (zh) | 2003-05-21 |
| EP1276738B8 (en) | 2008-02-20 |
| EP1136482A1 (en) | 2001-09-26 |
| ATE380806T1 (de) | 2007-12-15 |
| CY1107236T1 (el) | 2012-05-23 |
| CA2401241A1 (en) | 2001-09-27 |
| DE60131844T2 (de) | 2008-11-27 |
| EP1276738A1 (en) | 2003-01-22 |
| US20030187004A1 (en) | 2003-10-02 |
| US7378413B2 (en) | 2008-05-27 |
| KR20020093848A (ko) | 2002-12-16 |
| ES2296783T3 (es) | 2008-05-01 |
| PT1276738E (pt) | 2008-02-28 |
| US6844335B2 (en) | 2005-01-18 |
| AU2001281487A1 (en) | 2001-10-03 |
| WO2001070729A1 (en) | 2001-09-27 |
| AR028280A1 (es) | 2003-04-30 |
| DE60131844D1 (de) | 2008-01-24 |
| KR100820543B1 (ko) | 2008-04-07 |
| CA2401241C (en) | 2011-11-29 |
| CN1247567C (zh) | 2006-03-29 |
| JP4778657B2 (ja) | 2011-09-21 |
| JP2003528095A (ja) | 2003-09-24 |
| SI1276738T1 (sl) | 2008-06-30 |
| EP1276738B1 (en) | 2007-12-12 |
| CN1891220A (zh) | 2007-01-10 |
| US20050130998A1 (en) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1276738T3 (da) | 2-amino-3- (alkyl) - pyrimidinderivater som GSK3-betainhibitorer | |
| NO20030867L (no) | Hydroksamderivater anvendelig som deacetylaseinhibitorer | |
| DK1492785T3 (da) | 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer | |
| NO20023828L (no) | Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer | |
| NO20014642L (no) | Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer | |
| NO20043793L (no) | Nikotinamidderivater anvendelige som PDE4 inhibitorer | |
| DK1345922T3 (da) | Pyrazolforbindelser der er nyttige som proteinkinaseinhibitorer | |
| DK1318997T3 (da) | Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer | |
| DK1289985T3 (da) | Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer | |
| DE60130463D1 (de) | Pyrimidin-derivate | |
| NO20012701D0 (no) | Aryl- og heterosyklylsubstituerte pyrimidinderivater som antikoagulanter | |
| DK1337527T3 (da) | Indolylmaleinimidderivater som proteinkinase C-inhibitorer | |
| NO20052887D0 (no) | Pyridazinonderivater som GSK-3Beta inhibitorer. | |
| DK1244647T3 (da) | Quinzolinderivater som VIGF-inhibitorer | |
| EE200300195A (et) | Pürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid | |
| NO20014483D0 (no) | Aminderivater som proteaseinhibitorer | |
| NO20033618D0 (no) | Ftalayinon-piperidino-derivater som PDE-4-inhibitorer | |
| NO20024997D0 (no) | 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer | |
| NO20050665L (no) | Pyrrolidonderivater som MAOE inhibitoere | |
| NO20025811D0 (no) | Forbindelser som er effektive som beta-2-adrenoreseptor- anonister så vel som PDE4-inhibitorer | |
| DK1311488T3 (da) | Substituerede imidazoler som tafia-inhibitorer | |
| DK1438289T3 (da) | Indolderivater som cox II-inhibitorer | |
| NO20016201D0 (no) | Tienopyrimidiner som fosfodiesteraseinhibitorer | |
| NO20021959D0 (no) | Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer | |
| DK1651641T3 (da) | Nicotinamidderivater egnede som PDE4 inhibitorer |